8thANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE:

An Intensive Course on Translating Research into Drugs


Presented by the Alzheimer's Drug Discovery Foundation

February 2-4, 2014  ●  Miami, FL








Designed as a comprehensive course on the drug discovery process, from target validation through to clinical development, the annual Drug Discovery for Neurodegeneration conference provides participants with the fundamental knowledge and resources to translate their research into new drugs to treat and prevent Alzheimer's disease and related neurodegenerative diseases. 
 
Attendees from academia and industry will also learn from specific case studies examples and will have an opportunity to engage in interactive discussions on securing partnerships.

The program will include a focus on Alzheimerís disease, Parkinsonís disease and Multiple Sclerosis.

COURSE OBJECTIVES

1.
 

Train a cadre of interdisciplinary scientists in the principles of drug discovery for neurodegenerative disease

2.

Provide a platform to exchange ideas, knowledge and resources about drug discovery for neurodegenerative disease

3.

Stimulate pre-clinical research in the discovery and testing of novel compounds aimed at the prevention and treatment of neurodegenerative disease

4.

Build public-private partnerships that will accelerate drug discovery for neurodegenerative disease.
WHAT YOU WILL LEARN

1.

Challenges and opportunities in academic drug discovery
2. Fundamentals of medicinal chemistry relevant to drug discovery for neurodegenerative diseases
3. Newest trends in assay development and high throughput screening (HTS)
4. Go-no-go criteria for preclinical development, including pharmacokinetic behavior of candidate compounds, aqueous solubility, blood-brain barrier permeability, preliminary safety, and manufacturing issues
5. Study design considerations for animal model experiments
6. Biologics for challenging CNS targets and strategies to optimize brain delivery
7. Requirements for an Investigational New Drug (IND) application
8. Commercialization strategies for developing science into products
9. Best practices for working with tech transfer offices, managing intellectual property, and the role of funding organizations
10.

Funding & resources for preclinical therapeutics development for neurological disorders

SCIENTIFIC ADVISORY COMMITTEE

Howard Fillit, MD, Executive Director and Chief Science Officer, ADDF

Suzana Petanceska, PhD, Program Director, National Institute on Aging

D. Martin Watterson, PhD, Professor, Molecular Pharmacology & Biology Chemistry at Northwestern University; and Director, Drug Discovery Program

Kalpana Merchant, PhD, Eli Lilly and Company

Edward Spack, PhD, Managing Director, Fast Forward LLC

Marcie Glicksman, PhD, Co-Director at Lab for Drug Discovery, Harvard Medical School

Kurt R. Brunden, PhD, University of Pennsylvania

Frank Longo, MD, PhD, Professor and Chair Department of Neurology and Neurological Sciences, Stanford University

Rachel Lane, PhD, Assistant Director for Scientific Affairs, ADDF

Diana Shineman, PhD, Director for Scientific Affairs, ADDF

TARGET AUDIENCE

Academic and industry scientists engaged in drug discovery research for neurodegenerative disease or CNS

Business development and licensing professionals

Alliance management professionals

Young investigators and graduate students

ARCHIVED PROGRAMS

All pages will open in new windows:

NEW! 2014 Speaker Biographies, Abstracts and Session Videorecordings

(you can also review all videocasts from this link.)

2013 Agenda

2013 Speaker Biographies, Abstracts and Session Videorecordings

(you can also review all videocasts from this link.)

2012 Agenda and Webcast

review report published in Expert Opinion in Drug Discovery

2011 Agenda and Webcast

2010 Agenda and Webcast

2009 Agenda

2008 Agenda

2007 Agenda

 

 
The Drug Discovery for Neurodegeneration conference is presented by the Alzheimer's Drug Discovery Foundation (ADDF), the only public charity solely dedicated to rapidly accelerating the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging.